Project summary: Clinical, Social and Economic Impact Program
Developing System-level Policy Model for regenerative medicine and cell therapy in Oncology
April 23rd, 2018 to March 31st, 2020
HIGHLIGHTS
- Findings will address knowledge gaps in policy makers in the context of reimbursement of CAR T-cell therapy
- Provide cancer researchers with necessary support to make informed economic decisions regarding the development of future CAR T-cell therapy
- Research will contribute important insights to both clinical researchers and policy makers to improve oncology care in the Canadian health care system
About the Project
Chimeric antigen receptor T cells, or CAR T cells, have transformed oncology treatment, offering the potential to cure certain cancers. Although shown to be effective in selected populations, the high cost of CAR T-cell therapy, along with substantial usage of health care resources (highly personalized therapy and significant monitoring required) may potentially restrict patient access to this type of treatment in the future. A framework must be established to estimate the cost-effectiveness of this therapy compared to the standard of care by taking into account the effectiveness, safety, affordability and resource constraints in the Canadian healthcare system.
Dr. Wong’s team will use an innovative approach to establish a platform to support the decision- making process regarding reimbursement and implementation of CAR T-cell therapy in the future. Results of this research will provide an evidence-based evaluation of this therapy and its place in the health system, and serve as a foundation for clinical trial researchers and policy makers for improving oncology care.
